GLP-1 Medications and Mental Health Benefits: What New Research Shows

When GLP-1 medications first entered widespread use, their effects were viewed mainly through a metabolic lens. Appetite, reward, and impulse control are closely connected to mental health, and GLP-1 receptors are active in areas of the brain involved in mood, motivation, and behavior.

After several years of real-world use, consistent patterns have emerged. Some individuals report fewer intrusive food thoughts, reduced cravings for alcohol or other substances, and improved emotional regulation. These observations led researchers to explore whether GLP-1 medications might influence mental health directly, not only through weight loss.

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in appetite regulation, digestion, and insulin release. GLP-1 medications mimic this hormone’s effects in the body.

These medications work by:

• Slowing gastric emptying

• Increasing feelings of fullness

• Reducing hunger and food cravings

• Influencing reward pathways involved in eating behavior

Because appetite, reward, and impulse control are closely tied to mental health, GLP-1s may affect emotional and psychological functioning in ways that go beyond weight loss alone.

• Semaglutide
  Brand names include Ozempic, Wegovy, and Rybelsus.
  Ozempic is FDA-approved for diabetes, Wegovy is FDA-approved for weight loss, and Rybelsus is an oral tablet FDA-approved for type 2 diabetes.
• Tirzepatide
  Brand names include Mounjaro and Zepbound.
  Mounjaro is FDA-approved for diabetes, while Zepbound is FDA-approved for weight loss.
• Liraglutide
  Brand names include Victoza and Saxenda.
  Victoza is FDA-approved for diabetes, and Saxenda is FDA-approved for weight loss.
• Dulaglutide
  Brand name Trulicity.
  Trulicity is FDA-approved for diabetes and is sometimes discussed in the context of weight management.
• Exenatide
  Brand names include Byetta and Bydureon.
  Byetta and Bydureon are FDA-approved to treat type 2 diabetes. Byetta is taken twice daily, while Bydureon is a once-weekly extended-release injection.
• Lixisenatide
  Brand name Adlyxin.
  Adlyxin is FDA-approved for diabetes.

Some GLP-1 medications are taken as weekly injections, such as Ozempic, Wegovy, Trulicity, Bydureon, and Zepbound. Others are taken daily by injection, such as Victoza, Saxenda, and Byetta, or as a daily oral tablet, such as Rybelsus.

Although these medications share a common mechanism, individual experiences can vary based on the specific drug, dosage, and a person’s physical and mental health history. Always follow your prescribing clinician’s directions on medication dosage and timing.

According to a 2024 systematic review published in the National Library of Medicine, GLP-1 receptor agonists have been associated with several potential mental health benefits across animal and human studies. Key findings from this research include:

• Improvement in depressive symptoms
  This 2024 review found evidence that GLP-1 medications may help reduce symptoms of depression. These effects are thought to be related to anti-inflammatory and antioxidant processes in the brain, as well as changes in neurotransmitters involved in mood regulation.

• Better cognitive function
  Some studies included in this 2024 review showed improvements in cognitive areas such as attention, learning, and mental clarity. Researchers from those studies suggest this may be linked to improved brain signaling and reduced oxidative stress.

• Reductions in alcohol and substance use
  GLP-1 medications were associated with decreased alcohol consumption and reduced substance use in several studies from this 2024 review. These effects are believed to stem from changes in reward and impulse-control pathways in the brain.

• Decreases in binge eating behaviors
  This 2024 review also found that GLP-1 medications may help reduce binge eating by lowering appetite and food cravings. For some individuals, this may support better control over eating behaviors when combined with appropriate mental health care.

While research findings are promising, human experiences with GLP-1 medications are not identical. Some people notice emotional benefits, while others experience little change. Researchers point to several reasons for this variation, including differences between specific GLP-1 medications, individual mental health history, the presence of eating disorders or mood disorders, and differences in dosage, duration of use, and overall health. These differences highlight the importance of personalized care rather than a single approach for everyone.

One area where GLP-1 medications appear particularly helpful is in reducing binge eating and compulsive eating behaviors.

By decreasing appetite and cravings, these medications may help some individuals break cycles of emotional or impulsive eating. For certain patients, quieter hunger signals allow more effective participation in therapy and the development of healthier coping strategies.

However, appetite suppression alone does not treat eating disorders. Individuals with a history of restrictive eating, body dysmorphia, or disordered eating should use GLP-1 medications alongside mental health treatment. Therapy remains essential to help address underlying emotional patterns and prevent shifts toward other compulsive behaviors.

In January 2026, the U.S. Food and Drug Administration announced that it is requesting the removal of suicidal behavior and suicidal ideation warnings from certain GLP-1 receptor agonist medications. This decision followed a comprehensive FDA review that found no increased risk of suicidal thoughts or behaviors associated with GLP-1 use.

The FDA analyzed data from large clinical trials and real-world studies involving more than 100,000 patients and did not identify higher rates of suicide-related outcomes or serious psychiatric side effects compared to placebo or other diabetes treatments. Based on these findings, the FDA concluded that GLP-1 medications are not associated with an increased suicide risk and moved to update labeling for consistency across the drug class.

Even though current evidence suggests GLP-1 medications do not show an increased risk of suicidal thoughts or behaviors when used as prescribed, individuals should report any mood changes to their healthcare provider.

After several years of real-world use and growing scientific study, evidence suggests that GLP-1 medications may support mental health in addition to weight loss. Benefits related to mood, cognitive function, binge eating, and addictive behaviors appear to be biologically plausible and supported by emerging data. At the same time, careful screening and monitoring remain important, especially for individuals with eating disorders or mood disorders.

When mental health is taken into account during treatment planning, some may be more likely to experience positive outcomes. Open communication with healthcare professionals and ongoing monitoring may help ensure that both physical and psychological needs are addressed throughout the course of GLP-1 therapy.

GLP-1 medications should only be taken as prescribed by a qualified clinician. Individual experiences vary, and these medications may not be appropriate for everyone.